Oragenics preparing Phase II trial for concussion drug ONP-002; secures CRO, optimizes formulation

ORAGENICS INC

ONP-002 intranasal neurosteroid for mild TBI (concussion) advances to Phase II after positive Phase I safety.
Partnering with Avance Clinical for Phase IIa at level one trauma centers in Australia.
Formulation optimized to increase active compound percentage and target brain absorption within minutes.
Estimated 69 million concussion cases globally annually; up to 20% develop post-concussion syndrome.
Adequate intranasal device supply secured for upcoming trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.